NEW YORK and BERLIN, May 29, 2025 — (NASDAQ: ATAI) (“atai” or the “Company”), a biopharmaceutical company in the clinical stage focused on creating highly effective mental health treatments to improve patient results, today announced that the Company’s management team is scheduled to participate in the following investor conferences during the month of June:

Jefferies Global Healthcare Conference

• Format: Fireside Chat
• Date and Time: Thursday, June 5, at 9:55 A.M. Eastern Time
• Location: New York
• Webcast link:

H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

• Format: Pre-recorded Fireside Chat
• Date and Time: Tuesday, June 17, at 7:00 A.M. Eastern Time
• Location: Virtual
• Webcast link:

The webcasts of the fireside chats can also be found in the Investors section of the atai website under . A replay will be made available after the live event.

About atai Life Sciences
atai is a biopharmaceutical company at the clinical stage, dedicated to the development of highly effective mental health treatments with the goal of transforming patient outcomes. Our pipeline features psychedelic-based therapies such as VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder, both currently in Phase 2 clinical development. Additionally, we are furthering a drug discovery program aimed at identifying new, non-hallucinogenic 5-HT2AR agonists for TRD. These programs seek to address the complexities of mental health by delivering commercially viable interventional psychiatry therapies that can be easily integrated into healthcare systems. For the most recent updates and to discover more about our mission, please visit or follow us on .

Contact Information
Investor Contact:

Media Contact:

“`